Pyxis Oncology secured up to $114 million through a private placement led by BVF Partners to fund the development of its cancer drug MICVO. The financing will extend the company's cash runway into Q2 2027, supporting ongoing trials for head and neck squamous cell carcinoma. Updated Phase 1 monotherapy data is expected in Fall 2026, with combination therapy data due in Q4 2026. This funding strengthens Pyxis's ability to advance MICVO toward regulatory and clinical milestones, aiming to improve treatment for difficult cancers.
Analyst Ronald Kamdem from National Bank has set a $50 price target for NNN REIT, Inc., suggesting a 2.34% potential upside from its current price of $48.86. The REIT employs a disciplined capital recycling strategy, selling less profitable assets an...
Target is launching "Picolette," an exclusive baby collection by Olivia Culpo, featuring 60 stylish and affordable items to boost its baby product segment. The collection will be available in about 1,400 stores and online starting July 26, enhancing ...
Votito has launched a new product management platform designed to help small software teams decide what products to build by combining user feedback with product research. As AI tools make software development faster, the challenge shifts to understa...
Investar Holding Corporation reported strong Q2 2026 results, with earnings per share of $0.75, beating analyst estimates by 7.14%. Quarterly revenue reached $36.55 million, a 64.1% increase year-over-year, surpassing expectations. The company has co...
Personalis, a cancer testing firm, is being acquired by Tempus AI in a $1.5 billion all-stock deal offering $16.25 per share, a 28% premium. Despite the premium, Personalis shares dropped 13.39% on the announcement day due to capped upside until deal...
